Subscriber Content Preview | Request a free trialSearch  


In M&A, the Big Spend returns

Deals of $1 billion or more increased in the first quarter, but multiples aren't yet out of whack. Continue reading

More dealmaking is part of LifePoint's DNA

The financially flexible operator of 68 hospitals has already made a couple of deals this year. Continue reading

House panel looks at FTC's merger superpowers

Federal law and court rulings give the commission a boost over DOJ when taking deals to court. Continue reading

Foundering retailers drag malls into a failure vortex

The sad state of the industry has resulted in a profusion of boarded-up stores, "space for rent" signs and landlords scrambling for new tenants. The shopping centers that remain standing will likely look a lot different than they have in the past. Continue reading

U.S., Canada lay out merger cooperation steps

Regulators aim for transparency in cross-border antitrust reviews. Continue reading

Who to call when the barbarians are at the gate

The rise of activism has been a boon to a group of advisers who can coordinate offense and defense. If one of these names shows up in a regulatory filing as a recent hire, it's a pretty good indication that something's up. Continue reading

PE buyers get some competition for urgent care deals

Financial players have done most of the consolidation in the walk-in segment of the healthcare market, but hospital systems and other strategics have become more interested in participating. Continue reading

Last call at PE's happy hour

PE firms -- and their bosses -- take advantage of a seller's market in IPOs. Continue reading

The Deal's guide to activists: A program for proxy season

Who is our ace investor? And who deserves to sit on the bench? Probably not who you think. We recount the successes and failures of the biggest names in the activism game and identify a couple of newcomers to watch. Continue reading

Big pharma takes on the FTC

Major drug companies asking federal court to strike down new antitrust burdens for patent deals. The central issue is whether the agency can single out one industry for extra scrutiny. Continue reading

Move to Ireland could boost Questcor's M&A effort

An analyst says that the nation's business-friendly tax rate could create savings to be used for deals. Continue reading

Biotech boom may be bubble, B. Riley chairman says

The JOBS Act may be spurring hot biotech deals rather than the best companies. Continue reading

Meet the journalists

Pamela Taulbee

Senior Writer: Healthcare

Jim Cramer's 2013 M&A predictions

The Founder of and host of Mad Money makes his predictio ... Video

More Healthcare video

The Deal's Webcast Series

If you have not had the chance to enjoy our Webcast Series, now is the time. Join these free 60-minute discussions and get a handle on the latest strategies and tactics in private equity, cross-border and middle market dealmaking and more.

Industry Events

View information on all upcoming industry events which The Deal representatives are participating in.

The Deal Economy 2014

The improving U.S. economy presents opportunities for expansion, along with pitfalls that can trip even the most astute executives. Acquire, divest or sit tight…which strategy makes the best sense in 2014? The answers will reshape the deal landscape as fortunes are wagered, won and lost throughout the coming year.

The Deal on Twitter

Follow @TheDealNewsroom for the latest news across mergers and acquisitions, auctions, financings, restructurings and more!